Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. - Asset Resilience Ratio

Latest as of June 2025: 3.84%

Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096) has an Asset Resilience Ratio of 3.84% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does Hangzhou Bio-Sincerity Pharma-Tech Co.Lt carry for a breakdown of total debt and financial obligations.

Liquid Assets

CN¥148.64 Million

≈ $21.75 Million USD Cash + Short-term Investments

Total Assets

CN¥3.87 Billion

≈ $567.03 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2024–2024)

This chart shows how Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s Asset Resilience Ratio has changed over time. See shareholders equity of Hangzhou Bio-Sincerity Pharma-Tech Co.Lt for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Hangzhou Bio-Sincerity Pharma-Tech Co.Lt market cap and net worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥148.64 Million	3.84%
Total Liquid Assets	CN¥148.64 Million	3.84%

Asset Resilience Insights

Limited Liquidity: Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. maintains only 3.84% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. Industry Peers by Asset Resilience Ratio

Compare Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
AbbVie Inc NYSE:ABBV	Drug Manufacturers - General	0.02%
Roche Holding AG SW:ROG	Drug Manufacturers - General	15.37%
Biogen Inc NASDAQ:BIIB	Drug Manufacturers - General	2.74%
CSPC Pharmaceutical Group Limited F:CVG	Drug Manufacturers - General	4.64%
AstraZeneca PLC LSE:AZN	Drug Manufacturers - General	0.03%
Yifan Xinfu Pharmaceutical Co Ltd SHE:002019	Drug Manufacturers - General	0.53%
Hubei Guangji Pharmaceutical Co Ltd SHE:000952	Drug Manufacturers - General	5.37%
Dimed S.A. Distribuidora de Medicamentos SA:PNVL3	Drug Manufacturers - General	10.10%

Annual Asset Resilience Ratio for Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (2024–2024)

The table below shows the annual Asset Resilience Ratio data for Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd..

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	2.23%	CN¥83.00 Million ≈ $12.15 Million	CN¥3.72 Billion ≈ $544.53 Million	--

pp = percentage points

About Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.

SHE:301096 China Drug Manufacturers - General

Market Cap

$936.00 Million

CN¥6.40 Billion CNY

Market Cap Rank

#9390 Global

#2571 in China

Share Price

CN¥58.56

Change (1 day)

+4.66%

52-Week Range

CN¥34.37 - CN¥68.99

All Time High

CN¥98.58